2009/10 session 2010-01-20 seminar

The Applied Biostatistics Association, TABA,  invites you to a seminar and dinner…
Topic: Dynamic Allocation methods: Why the controversy?  (See abstract below)

Speaker: Greg Pond, McMaster University

When: Wednesday, January 20, 2010
6-7 pm seminar
7 pm dinner (optional, but pre-registration required)

Where: Room 7-605, Princess Margaret Hospital, 610 University Avenue

Cost: Seminar – free
Dinner – $15  (students $5)

Please RSVP to Tina Haller  by Sunday January 10th if you plan to attend the seminar or the dinner (see dinner cancellation policy below).

If you plan to attend the dinner, please mail a cheque payable to TABA to

Tina Haller
xxxxxxxxxxxxx
xxxxxxxx
xxxxxx

If you have signed up for dinner, and have to cancel, we request a 48 hour notice.  Otherwise, TABA does have to pay for the dinner, and we will have to pass the cost back onto you.

********************************************************************
TABA seminars are made possible thanks in part to generous donations from McDougall Scientific Ltd, Purdue Pharma and Amgen Canada

If you would like to see your company name here as a sponsor, please contact Tina Haller or Ruth Croxford
(taba.exec@gmail.com).
*********************************************************************

Dynamic Allocation methods: Why the controversy?

Use of dynamic allocation [DA] methods, aka minimization, has been reported in the literature as ‘infrequently used’, with noted concerns about the administrative burden and validity of these methods. Others claim DA methods produce more credible results and should be considered the ‘gold standard’ for patient allocation in clinical trials. This talk will discuss the basis for this controversy and highlight some recent work about DA methodology. I will then summarize findings from a literature review of cancer clinical trials published over a 10-year period, including a comparison of different patient allocation methods (DA, stratified random sampling, simple random sampling) and findings concerning the perceived validity and credibility of DA methods amongst cancer clinical trial researchers.

We look forward to seeing you there!
TABA excutive:
Ruth Croxford, President
Reid Robson, Vice President
Tina Haller, Treasurer
Lorinda Simms, Secretary
Marguerite Ennis, Secretary

Leave a Reply

Your email address will not be published. Required fields are marked *